Neha Jalan is a Professional Services Solutions Manager at QIAGEN Digital Insights in North America. Neha has spent over a decade working in genomics, bioinformatics and microbiology; while interacting with scientists and providing solutions for their research concerns. Prior to joining QIAGEN, Neha gained her experience at Eurofins Scientific and Altria. Dr. Jalan earned her Ph.D. In Microbiology and Cell Science from the University of Florida and MSc in Microbiology from University of Mumbai.

Sheryl Krevsky Elkin, PhD, is the Chief Scientific Officer for QIAGEN Digital Insights, Oncology. Dr. Elkin joined QIAGEN in 2019 as part of a merger with N-of-One, a clinical interpretation company. An early member of the N-of-One team, Dr. Elkin played a lead role in the development of the N-of-One clinical interpretation methodology, establishing a rigorous process for the analysis of scientific and clinical evidence and presentation of the evidence to physicians to help guide their therapeutic decisions. At QIAGEN Digital Insights, Dr. Elkin helped to integrate expert clinical interpretation into QIAGEN’s clinical decision support software and is responsible for scientific oversight of the oncology products. Dr. Elkin completed her postdoctoral fellowship at the Massachusetts Institute of Technology’s Center for Cancer Research, where she earned a fellowship from the Leukemia and Lymphoma Society. She earned her doctorate in Biological and Biomedical Sciences from Harvard Medical School and an A.B. in Biology and Music from Amherst College, graduating Phi Beta Kappa and summa cum laude, with High Distinction in Biology.

Umadevi Thirumurthi, PhD, is the Associate Director of Global Product Management, Somatic Oncology at QIAGEN Digital Insights. Prior to joining QIAGEN in Nov 2022, Dr. Thirumurthi was at Sema4 (now GeneDx), where she played a lead role in the development of their in-house Cancer Knowledgebase to support clinical reporting of the Sema4 Solid Tumor and Whole Exome/Transcriptome tests. During her tenure at Sema4, besides supporting the clinical oncology workflow, she was also instrumental in building tools and software solutions in collaboration with bioinformatics and software units and closely working with the business development, marketing, and product units within Sema4 to assist in launching oncology products into the market. Other past work included identifying novel pathways to target cancer stem cells at Merrimack Pharmaceuticals. Dr. Thirumurthi has a Ph.D. in Cancer Biology from UTHSC MD Anderson Cancer Center and a Master’s in Molecular Biotechnology from Wayne State University.